The Impact of Some Natural Phenolic Compounds on α-Glucosidase and Sorbitol Dehydrogenase Enzymes, and Anti-leukemia Cancer Potential, Spin Density Distributions, and in silico Studies.

In this study, some phenolic compounds including 4-Hexylresorcinol, 5-Pentadecylresorcinol, 5-Tricosylresorcinol, Bilobol, and Urushiol were tested against α-glycosidase enzyme from Saccharomyces cerevisiae and sorbitol dehydrogenase enzymes from sheep liver. These compounds determined good inhibition properties against α-glycosidase and sorbitol dehydrogenase (SDH) enzymes. IC50 values were record in the range of 1.45±0.20-24.532±3.83 µM for α-glycosidase and 6.20±0.96-108.22±18.02 µM for SDH. These inhibitor compounds can be selective drug candidates as anti-diabetic agents, because of they have inhibition properties against both enzymes. In this study, the anti-oxidant activities of the molecules were compared with density functional theory (DFT) calculations. Comparison was made with the experimental enzymes by molecular modeling calculations. In the cellular and molecular part of the recent study, the treated cells with some phenolic compounds were assessed by molecularly targeted therapy (MTT) assay for cytotoxicity and anti-acute lymphoblastic leukemia potentials on Clone 15 HL-60, HL-60, HL-60/MX1, and HL-60/MX2 cell lines. The IC50 of these compounds were µg/mL level against these cell lines.

Prevalence and clinical outcomes of hepatitis B virus infection in patients with aplastic anemia.

The association of HBV infection with other hematopoietic diseases has been discussed previously. However, the clinical significance and clinical outcomes of HBV infection in AA patients have not been clarified. In this study, we sought to investigate the prevalence and related events of HBV in patients with AA who received immunosuppressive therapy. We retrospectively analyzed 245 patients with acquired AA. The HBsAg positivity rate was 14.69% in this group of AA patients. No significant difference was observed in the severity of AA patients with HBV infection and in those without (P = 0.6358). HBV reactivation occurred in 4.76% of HBsAg-positive patients who received ATG/ALG + CsA treatment without anti-viral prophylaxis. HBV-infected patients who received CsA alone did not develop reactivation. Patients with HBV reactivation showed favorable clinical outcomes, with no HBV-related deaths. There was no significant difference in overall probability of survival in patients with different HBV infection status (P = 0.8617). Given the low rate of reactivation and favorable outcomes after reactivation in AA patients, close monitoring of HBV DNA, hepatic function and patient immune status may be a more effective approach than routine prophylaxis for AA patients with HBV infection undergoing ATG/ALG + CsA treatment. Further studies are warranted to clarify the optimal time to initiate anti-viral treatment.